Home Cart 0 Sign in  
X

[ CAS No. 108-00-9 ]

{[proInfo.proName]} ,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
3d Animation Molecule Structure of 108-00-9
Chemical Structure| 108-00-9
Chemical Structure| 108-00-9
Structure of 108-00-9 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Bulk Inquiry Add To Cart

Quality Control of [ 108-00-9 ]

Related Doc. of [ 108-00-9 ]

Alternatived Products of [ 108-00-9 ]

Product Details of [ 108-00-9 ]

CAS No. :108-00-9 MDL No. :MFCD00008175
Formula : C4H12N2 Boiling Point : -
Linear Structure Formula :- InChI Key :DILRJUIACXKSQE-UHFFFAOYSA-N
M.W :88.15 Pubchem ID :66053
Synonyms :

Calculated chemistry of [ 108-00-9 ]

Physicochemical Properties

Num. heavy atoms : 6
Num. arom. heavy atoms : 0
Fraction Csp3 : 1.0
Num. rotatable bonds : 2
Num. H-bond acceptors : 2.0
Num. H-bond donors : 1.0
Molar Refractivity : 26.95
TPSA : 29.26 Ų

Pharmacokinetics

GI absorption : Low
BBB permeant : No
P-gp substrate : No
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -7.32 cm/s

Lipophilicity

Log Po/w (iLOGP) : 1.42
Log Po/w (XLOGP3) : -0.68
Log Po/w (WLOGP) : -0.49
Log Po/w (MLOGP) : -0.18
Log Po/w (SILICOS-IT) : -0.87
Consensus Log Po/w : -0.16

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 2.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : 0.17
Solubility : 132.0 mg/ml ; 1.49 mol/l
Class : Highly soluble
Log S (Ali) : 0.54
Solubility : 306.0 mg/ml ; 3.47 mol/l
Class : Highly soluble
Log S (SILICOS-IT) : -0.34
Solubility : 40.3 mg/ml ; 0.457 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.0

Safety of [ 108-00-9 ]

Signal Word:Danger Class:3,8
Precautionary Statements:P501-P270-P240-P210-P233-P243-P241-P242-P264-P280-P370+P378-P303+P361+P353-P301+P330+P331-P363-P301+P312+P330-P304+P340+P310-P305+P351+P338+P310-P403+P235-P405 UN#:2733
Hazard Statements:H225-H302-H314 Packing Group:
GHS Pictogram:

Application In Synthesis of [ 108-00-9 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 108-00-9 ]
  • Downstream synthetic route of [ 108-00-9 ]

[ 108-00-9 ] Synthesis Path-Upstream   1~17

  • 1
  • [ 75-44-5 ]
  • [ 108-00-9 ]
  • [ 80-73-9 ]
Reference: [1] Spectrochimica Acta, Part A: Molecular and Biomolecular Spectroscopy, 1983, vol. 39, # 10, p. 929 - 932
  • 2
  • [ 67-56-1 ]
  • [ 107-15-3 ]
  • [ 110-18-9 ]
  • [ 142-25-6 ]
  • [ 108-00-9 ]
  • [ 109-81-9 ]
  • [ 110-70-3 ]
Reference: [1] Patent: JP2005/41806, 2005, A, . Location in patent: Page/Page column 8
  • 3
  • [ 926-64-7 ]
  • [ 108-00-9 ]
Reference: [1] Crisol, 1953, vol. 7, p. 19,21,22
[2] Journal of the American Chemical Society, 1942, vol. 64, p. 2232
[3] Journal of the American Chemical Society, 1946, vol. 68, p. 1607
[4] Bulletin de la Societe Chimique de France, 1955, p. 218
[5] Patent: US2232598, 1938, ,
  • 4
  • [ 506-59-2 ]
  • [ 870-24-6 ]
  • [ 108-00-9 ]
Reference: [1] Patent: CN107619390, 2018, A, . Location in patent: Paragraph 0014
  • 5
  • [ 383865-57-4 ]
  • [ 108-00-9 ]
Reference: [1] Patent: US2002/45615, 2002, A1,
  • 6
  • [ 67-56-1 ]
  • [ 107-15-3 ]
  • [ 108-00-9 ]
  • [ 109-81-9 ]
  • [ 110-70-3 ]
Reference: [1] Journal of the American Chemical Society, 2004, vol. 126, # 23, p. 7368 - 7377
  • 7
  • [ 151-56-4 ]
  • [ 124-40-3 ]
  • [ 108-00-9 ]
Reference: [1] Bulletin of the Academy of Sciences of the USSR, Division of Chemical Science (English Translation), 1987, vol. 36, # 4, p. 873 - 874[2] Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya, 1987, # 4, p. 946 - 948
[3] Canadian Journal of Chemistry, 1956, vol. 34, p. 1567,1569
[4] Magnetic Resonance in Chemistry, 2013, vol. 51, # 7, p. 431 - 434
[5] Research on Chemical Intermediates, 2015, vol. 41, # 7, p. 4511 - 4522
  • 8
  • [ 20320-52-9 ]
  • [ 108-00-9 ]
Reference: [1] Farmaco, Edizione Scientifica, 1956, vol. 11, p. 607,613[2] Chem.Abstr., 1957, p. 1971
[3] CHEMTECH, 1959, vol. 11, p. 323
[4] Monatshefte fuer Chemie, 1981, vol. 112, p. 825 - 840
[5] Bioorganic and Medicinal Chemistry Letters, 2003, vol. 13, # 13, p. 2131 - 2135
  • 9
  • [ 927-90-2 ]
  • [ 108-00-9 ]
Reference: [1] DRP/DRBP Org.Chem.,
[2] DRP/DRBP Org.Chem.,
  • 10
  • [ 926-39-6 ]
  • [ 124-40-3 ]
  • [ 108-00-9 ]
Reference: [1] DRP/DRBP Org.Chem.,
[2] DRP/DRBP Org.Chem.,
  • 11
  • [ 67-56-1 ]
  • [ 107-15-3 ]
  • [ 110-18-9 ]
  • [ 142-25-6 ]
  • [ 108-00-9 ]
  • [ 109-81-9 ]
  • [ 110-70-3 ]
Reference: [1] Patent: JP2005/41806, 2005, A, . Location in patent: Page/Page column 8
  • 12
  • [ 22483-15-4 ]
  • [ 108-00-9 ]
Reference: [1] Journal of Organic Chemistry, 1970, vol. 35, p. 340 - 344
  • 13
  • [ 574-98-1 ]
  • [ 124-40-3 ]
  • [ 108-00-9 ]
Reference: [1] Fortschr. Teerfarbenfabr. Verw. Industriezweige, vol. 17, p. 2450
[2] Fortschr. Teerfarbenfabr. Verw. Industriezweige, vol. 17, p. 2450
  • 14
  • [ 151-56-4 ]
  • [ 124-40-3 ]
  • [ 108-00-9 ]
  • [ 24229-53-6 ]
Reference: [1] Canadian Journal of Chemistry, 1956, vol. 34, p. 1567,1569
  • 15
  • [ 111-26-2 ]
  • [ 91907-70-9 ]
  • [ 53054-00-5 ]
  • [ 108-00-9 ]
Reference: [1] Chemical Science, 2015, vol. 6, # 1, p. 144 - 151
  • 16
  • [ 498-94-2 ]
  • [ 24424-99-5 ]
  • [ 108-00-9 ]
  • [ 84358-13-4 ]
YieldReaction ConditionsOperation in experiment
94% With triethylamine In dichloromethane 1-(1,1-Dimethylethoxycarbonyl)Piperidine-4-Carboxylic Acid
Di-t-butyldicarbonate (23.42 g, 107.3 mmol) in dichloromethane (100 mL) was added slowly to a mixture of 4-piperidinecarboxylic acid (12.60 g, 97.6 mmol) and triethylamine (13.60 mL, 9.87 g, 97.6 mmol) in dichloromethane (50 mL) and the mixture was stirred at room temperature for 18 h. N,N-Dimethylethylenediamine (3.46 mL, 2.87 g, 32.5 mmol) was added and the mixture was stirred at room temperature for 30 min.
Dichloromethane (100 mL) was added and the mixture was washed with aqueous citric acid (10percent, 2*200 mL), dried (MgSO4) and the solvent was evaporated under reduced pressure to give the title compound as a colorless solid (21.05 g, 94percent).
1H NMR (250MHz, CDCl3) δ4.02 (2H, m), 2.86 (2H, m), 2.49 (1H, m), 1.91 (2H, m), 1.64 (2H, m), and 1.46 (9H, s).
Reference: [1] Patent: US2001/39286, 2001, A1,
  • 17
  • [ 108-00-9 ]
  • [ 63127-04-8 ]
  • [ 896705-16-1 ]
YieldReaction ConditionsOperation in experiment
58%
Stage #1: With O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate; N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide at 20℃; for 0.25 h;
Stage #2: for 16 h;
Method A: Synthesis of amide analogues (4). N-[2-(dimethylamino)ethyl]-12- oxo-12H-benzo[g]pyrido[2, l-b]quinazoline-4-carboxamide.
To a solution of 12-oxo-12H- benzo[g]pyrido[2, l-b]quinazoline-4-carboxylic acid (50.mg, 0.17 mmol) and TBTU (82.9 mg, 0.26 mmol) in DMF (1 mL) was added DIPEA (90 μ, 0.52 mmol). After the contents were stirred at room temperature for 15 minutes, N,N-dimethylethylenediamine (28.4 μ^, 0.26 mmol) was added, and stirring continued for 16 hours (for convenience). Added reaction mixture to 100 mL cold water with stirring. Collected solid by filtration and dried under vacuum to give N-[2-(dimethylamino)ethyl]-12-oxo-12H-benzo[g]pyrido[2, l- b]quinazoline-4-carboxamide (36 mg, 0.10 mmol, 58.0 percent yield) as a yellow solid. 1H NMR (400 MHz, DMSO-d6) δ ppm 11.50 (br. s., 1 H) 9.10 (s, 1 H) 8.91 (d, J=5.81 Hz, 1 H) 8.55 (d, J=5.56 Hz, 1 H) 8.28 - 8.34 (m, 2 H) 8.12 (d, J=8.34 Hz, 1 H) 7.73 (t, J=7.45 Hz, 1 H) 7.61 (t, J=7.33 Hz, 1 H) 7.05 (t, J=7.07 Hz, 1 H) 3.56 (d, J=5.05 Hz, 2 H) 2.59 (t, J=5.94 Hz, 2 H) 2.40 (s, 6 H). 1H NMR (400 MHz, CDC13) δ ppm 1 1.70 (br. s., 1 H) 9.10 (s, 1 H) 8.94 (dd, J=7.33, 1.77 Hz, 1 H) 8.73 (dd, J=6.82, 1.77 Hz, 1 H) 8.29 (s, 1 H) 8.12 (d, J=8.59 Hz, 1 H) 8.00 (d, J=8.34 Hz, 1 H) 7.66 (t, J=7.58 Hz, 1 H) 7.52 - 7.60 (m, 1 H) 6.89 (t, J=7.07 Hz, 1 H) 3.66 - 3.77 (m, 2 H) 2.71 (t, J=6.06 Hz, 2 H) 2.49 (s, 6 H). MS [M+l] = 361.
Reference: [1] Journal of Medicinal Chemistry, 2014, vol. 57, # 11, p. 4950 - 4961
[2] Patent: WO2015/143293, 2015, A1, . Location in patent: Paragraph 0084
Same Skeleton Products
Historical Records

Related Functional Groups of
[ 108-00-9 ]

Aliphatic Chain Hydrocarbons

Chemical Structure| 326888-32-8

[ 326888-32-8 ]

N1,N1,N2-Trimethylethane-1,2-diamine dihydrochloride

Similarity: 0.92

Chemical Structure| 100-36-7

[ 100-36-7 ]

N1,N1-Diethylethane-1,2-diamine

Similarity: 0.92

Chemical Structure| 52198-62-6

[ 52198-62-6 ]

N1,N1-Diethylethane-1,2-diamine dihydrochloride

Similarity: 0.85

Chemical Structure| 111-74-0

[ 111-74-0 ]

N,N'-Diethylethylenediamine

Similarity: 0.75

Chemical Structure| 616-39-7

[ 616-39-7 ]

N,N-Diethylmethylamine

Similarity: 0.75

Amines

Chemical Structure| 326888-32-8

[ 326888-32-8 ]

N1,N1,N2-Trimethylethane-1,2-diamine dihydrochloride

Similarity: 0.92

Chemical Structure| 100-36-7

[ 100-36-7 ]

N1,N1-Diethylethane-1,2-diamine

Similarity: 0.92

Chemical Structure| 4038-92-0

[ 4038-92-0 ]

N,N-Diethyl-2-(piperazin-1-yl)ethanamine

Similarity: 0.85

Chemical Structure| 98545-15-4

[ 98545-15-4 ]

N-Methyl-2-(4-methylpiperazin-1-yl)ethanamine

Similarity: 0.85

Chemical Structure| 4489-46-7

[ 4489-46-7 ]

2-(4-Ethylpiperazin-1-yl)ethanamine

Similarity: 0.85